Ameritas Investment Partners’s Lucid Diagnostics LUCD Stock Holding History

Ameritas Investment Partners’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.13K	Hold	7,067	–	–	﹤0.01%	2904
2025 Q4	$7.7K	Hold	7,067	–	–	﹤0.01%	2964
2025 Q3	$7.14K	Hold	7,067	–	–	﹤0.01%	3013
2025 Q2	$8.13K	Buy	+7,067	New	+$9.13K	﹤0.01%	3034
2022 Q2	–	Sell	-390	Closed	-$1K	–	3163
2022 Q1	$1K	Hold	390	–	–	﹤0.01%	3064
2021 Q4	$2K	Buy	+390	New	+$3.17K	﹤0.01%	3094

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Ameritas Investment Partners's LUCD Position: Q1 2026 in Review

Ameritas Investment Partners held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 7,067 shares worth $8.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2904.

Ameritas Investment Partners first reported a position in LUCD in Q4 2021 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Ameritas Investment Partners held 7,067 shares of Lucid Diagnostics worth $8.13K as of Q1 2026.
Ameritas Investment Partners left its Lucid Diagnostics share count unchanged in Q1 2026.
Lucid Diagnostics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2904 holding.
Ameritas Investment Partners first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 6 quarters since.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.